Urothelial Cancer Treatment Combination Fails To Meet OS End Points
September 19th 2020Neither monotherapy with durvalumab or combination treatment with durvalumab plus tremelimumab met co-primary end points of overall survival vs chemotherapy for the treatment of metastatic urothelial cancer.
Read More
Nivolumab/Ipilimumab Combo Shows Durable Benefit at 4 Years in Advanced RCC
September 19th 2020The benefits conferred by the combination of nivolumab and ipilimumab for the first-line treatment of advanced renal cell carcinoma remained durable after 4-year follow-up compared with treatment with sunitinib.
Read More